Results 21 to 30 of about 2,343,487 (194)

Expression analysis elucidates the roles of Nicastrin, Notch4, and Hes1 in prognosis and endocrine-therapy resistance in ER-positive breast cancer patients

Research in Pharmaceutical Sciences, 2023
Background and purpose: Although some proposed mechanisms responsible for tamoxifen resistance have already been present, further study is needed to determine the mechanisms underlying tamoxifen resistance more clearly.
Arad Boustan, Rosa Jahangiri, Asefeh Dahmardeh Ghalehno, Mahdieh Khorsandi, Fatemeh Mosaffa, Khadijeh Jamialahmadi   +5 more
doaj   +1 more source

A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen [PDF]

, 2012
SynthSys is a Centre for Integrative Systems Biology (CISB) funded by BBSRC and EPSRC, reference BB/D019621/1.Background: Estrogen receptors alpha (ER) are implicated in many types of female cancers, and are the common target for anti-cancer therapy ...
Harrison, David J, Kenneth Macleod, Yamaguchi, Azusa, Macleod, Kenneth, Galina Lebedeva, David J Harrison, Lebedeva, Galina, Langdon, Simon P., Langdon, Simon P, Azusa Yamaguchi, Harrison, David J., Simon P Langdon, Harrison, David J.; id_orcid   +12 more
core   +1 more source

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors

Molecular Cancer, 2010
Background Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2.
Richer Jennifer K, Edgerton Susan M, Spoelstra Nicole S, Das Partha M, Cittelly Diana M, Thor Ann D, Jones Frank E   +6 more
doaj   +1 more source

Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer

Life, 2022
NCOR2 is a co-repressor for estrogen receptor (ER) and androgen receptor (AR). Our group previously identified a novel splice variant of NCOR2, BQ323636.1 (BQ), that mediates tamoxifen resistance via interference of NCOR2 repression on ER.
Ho Tsoi, Ling Shi, Man-Hong Leung, Ellen P. S. Man, Zi-Qing So, Wing-Lok Chan, Ui-Soon Khoo   +6 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Italian randomized trial among womenwith histerectomy: tamoxifen and hormone-dependent breast cancer in hight-risk women [PDF]

, 2003
Tamoxifen improves outcome in women with breast cancer and reduces the incidence of estrogen receptor-positive (ER+) breast tumors in prevention trials. Tamoxifen use is associated with an increased risk of potentially serious adverse events, principally
MAISSONEUVE P, ROTMENSZ N, VERONESI U, PAGNI, Paola, COSTA A, Italian Tamoxifen Study Group:   +5 more
core   +1 more source

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.

PLoS ONE, 2014
Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, most breast tumors develop tamoxifen resistance and are eventually refractory to tamoxifen therapy.
Li Yin, Xin-Tian Zhang, Xiu-Wu Bian, Yu-Ming Guo, Zhao-Yi Wang   +4 more
doaj   +1 more source

Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway

Translational Oncology, 2020
Tamoxifen is a successful endocrine therapy drug for estrogen receptor–positive (ER+) breast cancer. However, resistance to tamoxifen compromises the efficacy of endocrine treatment.
Yijie Fu, Zhu Wang, Chuanxu Luo, Yu Wang, Yanping Wang, Xiaorong Zhong, Hong Zheng   +6 more
doaj   +1 more source

Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo

, 2004
We investigated whether it is possible to reduce anti-estrogen resistance using liposomally encapsulated tamoxifen in vivo. Small liposomal vesicles containing up to 5.1 mg tamoxifen/ml liposomal suspension, together with an alkylphospholipid to enhance ...
Zeisig, Reiner, Rückerl, Dominik; id_orcid, Fichtner, Iduna   +2 more
core   +6 more sources

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer [PDF]

, 2008
Increasing duration of tamoxifen therapy improves survival in women with breast cancer but the impact of adherence to tamoxifen on mortality is unclear. This study investigated whether women prescribed tamoxifen after surgery for breast cancer adhered to
Crilly, M., C McCowan, Donnan, P.T., T P Fahey, McCowan, C., Shearer, J., Fahey, T. P., Thompson, A. M., P T Donnan, Donnan, P. T.; id_orcid, Dewar, J.A., Dewar, J. A., J A Dewar, A M Thompson, Thompson, A.M., Fahey, T.P., M Crilly, J Shearer, McCowan, C.; id_orcid   +18 more
core   +1 more source